{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:42:05Z","timestamp":1790743325972,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.clinthera.2012.04.001","type":"journal-article","created":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T21:45:24Z","timestamp":1335217524000},"page":"1182-1194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Gemigliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Crossover Drug\u2013Drug Interaction Study in Healthy Male Korean Volunteers"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct01426906","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yook-Hwan","family":"Noh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong-Seok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Joon","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Jo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryoung","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Youn","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyun-Seop","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.04.001_bib1","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.04.001_bib2","first-page":"639","article-title":"Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review","volume":"26","author":"Wani","year":"2008","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.clinthera.2012.04.001_bib3","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diabetes.47.11.1663","article-title":"Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes","volume":"47","author":"Holst","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2012.04.001_bib4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.clinthera.2008.10.013","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study","volume":"30","author":"Lim","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.04.001_bib5","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1463-1326.2010.01303.x","article-title":"A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes","volume":"12","author":"Rhee","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2012.04.001_bib6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1365-2125.2009.03376.x","article-title":"Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers","volume":"68","author":"Lim","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.04.001_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","article-title":"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance","volume":"38","author":"Venkatakrishnan","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.04.001_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-0711-5-3","article-title":"Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor","volume":"5","author":"Chen","year":"2006","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.clinthera.2012.04.001_bib9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/01.fpc.0000215070.52212.0e","article-title":"Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin","volume":"16","author":"Niemi","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clinthera.2012.04.001_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0009-9236(96)90018-1","article-title":"Rifampin drastically reduces plasma concentrations and effects of oral midazolam","volume":"59","author":"Backman","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2012.04.001_bib11","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1208\/ps010418","article-title":"Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4","volume":"1","author":"Achira","year":"1999","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.clinthera.2012.04.001_bib12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.04.001_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.04.001_bib14","first-page":"443","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective","volume":"43","author":"Bjornsson","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.04.001_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0091270010367428","article-title":"Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants","volume":"51","author":"Tanaka","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.04.001_bib17","first-page":"45","article-title":"ICH harmonized tripartite guideline","volume":"47","year":"2001","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.clinthera.2012.04.001_bib18","first-page":"41","article-title":"The Declaration of Helsinki [in Italian]","volume":"29","year":"2010","journal-title":"Assist Inferm Ric"},{"key":"10.1016\/j.clinthera.2012.04.001_bib19","series-title":"Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications","year":"2011"},{"key":"10.1016\/j.clinthera.2012.04.001_bib20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.clpt.6100054","article-title":"Drug interaction studies: study design, data analysis, and implications for dosing and labeling","volume":"81","author":"Huang","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2012.04.001_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-4347(00)00122-5","article-title":"Specific determination of urinary 6beta-hydroxycortisol and cortisol by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry","volume":"746","author":"Ohno","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.clinthera.2012.04.001_bib22","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2165\/11201170-000000000-00000","article-title":"Saxagliptin","volume":"69","author":"Dhillon","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2012.04.001_bib24","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1124\/dmd.108.026088","article-title":"Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections","volume":"37","author":"Fura","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2012.04.001_bib25","article-title":"Onglyza (saxagliptin) tablets [prescribing information]","year":"2011"},{"key":"10.1016\/j.clinthera.2012.04.001_bib26","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1185\/03007990903178735","article-title":"Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes","volume":"25","author":"Rosenstock","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2012.04.001_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5414\/CP201568","article-title":"Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers","volume":"50","author":"Kim","year":"2012","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812002433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812002433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:48:57Z","timestamp":1758962937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812002433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0149291812002433"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.04.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Gemigliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Crossover Drug\u2013Drug Interaction Study in Healthy Male Korean Volunteers","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier HS Journals, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}